Advisory
AllSci
Stanford researchers, in collaboration with UCSF, have developed DESynR, a platform for engineering synthetic transcription factors that enhance CAR-T cell performance. Published in Cell, the study demonstrated that these engineered cells resist exhaustion and maintain tumor-fighting activity longer than conventional CAR-T cells. The research was led by Stanford’s Ansuman Satpathy and Theodore Roth.
DESynR allows scientists to recombine protein domains to create new regulatory programs, addressing a critical limitation in CAR-T therapies for solid tumors. Preclinical models showed improved survival rates and reduced tumor burden in mice, highlighting its potential to expand CAR-T therapy’s applicability to previously untreatable cancers.
Investment implication: This innovation addresses a key challenge in immunotherapy and positions Stanford as a leader in advancing CAR-T technology. For you, it signals potential opportunities in biotech collaborations and funding for next-generation cancer treatments.